Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Gains and losses of DNA are prevalent in cancer and emerge as a consequence of inter-
related processes of replication stress, mitotic errors, spindle multipolarity and breakage …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

The genome of each cell in the human body is constantly under assault from a plethora of
exogenous and endogenous processes that can damage DNA. If not successfully repaired …

Clear cell renal cell carcinoma (ccRCC) is a complex disease with remarkable immune and
metabolic heterogeneity. Here we perform genomic, transcriptomic, proteomic, metabolomic …

Although chemotherapy plus PD-1 blockade (chemo+ anti-PD-1) has become the standard
first-line therapy for advanced esophageal squamous cell carcinoma (ESCC), reliable …

Background: The APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like) family-mediated mutagenesis is widespread in human cancers. However, our …

The genomic origin and development of the biphasic lung adenosquamous carcinoma
(ASC) remain inconclusive. Here, we derived potential evolutionary trajectory of ASC …

The genomic spectrum of rhabdomyosarcoma (RMS) progression from primary to relapse is
not fully understood. In this pilot study, we explore the sensitivity of various targeted and …

MYC amplifications have been frequently detected in radiation (RT)‐associated
angiosarcomas (ASs) by low‐resolution molecular methods. However, large‐scale next …